

COVID-19 Vaccines

Vaccine	Pfizer-BioNTech	Moderna	Janssen (J&J)
	6 doses per vial	10 doses per vial	5 doses per vial
Vaccine Type	mRNA	mRNA	Replication – incompetent adenovirus type 26 vector
Authorized Age	FDA Approved for ≥ 12 years	FDA Approved for ≥ 12 years	EUA for ≥ 18 years
Dilution Required	No		
Expiration after opened	12 hours Room temperature **Leave remaining doses in vial until ready to use**	12 hours Room temperature	6 hours, refrigerated 2 hours, room temperature
Observation Period	Suggested but not required	Suggested but not required	Follow EUA Fact Sheet 15 to 30 minutes based on risk factors
Dose	Initial Series & Booster Dose: 0.3 mL	Initial Series & 3 rd dose for immunocompromised*: 0.5 mL Booster Dose: 0.25 mL	Initial & First Booster Dose [‡] : 0.5 mL
Number of Doses in Initial Series	2 doses 21 days apart	2 doses 28 days apart	1 dose
Immunocompromised Eligible for Additional Vaccination in Primary Series	28 days after completion of initial series	28 days after completion of initial series	Pfizer or Moderna at least 28 days after 1 st dose
Timing of Booster Dose	Age 18+[@]: 3 months after completion of initial series	Age 18+[@]: 3 months after completion of initial series	Any COVID-19 vaccine at least 2 months after additional dose
Timing of 2 nd Booster [‡]	4 months after 1st booster	4 months after 1st booster	N/A

*Immunocompromised: undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html>

^*If mRNA vaccine is desired following initial JJ dose, then okay to administer 2 months after first dose.

@: Booster doses are not currently recommended for individuals aged 12 to 17.

‡2nd booster of Pfizer or Moderna may be administered to individuals 50 years of age and older. 2nd Pfizer booster may be administered to individuals 12 years of age and older with certain kinds of immunocompromise. 2nd Moderna booster may be administered to individuals 18 years of age and older with certain kinds of immunocompromise. *Johnson & Johnson is not approved for second booster dose.*

Vaccine	Pfizer-BioNTech Age 6 Months to 4 Years	Pfizer-BioNTech Age 5 to 11	Moderna Age 6 Months to 5 Years	Moderna Age 6 to 11
	10 does per vial after dilution	10 doses per vial after dilution	10 doses per vial	5 doses per vial
Vaccine Type	mRNA			
Authorized Age	EUA for 6 months to 4 years [^]	EUA for 5 to 11 years	EUA for 6 months to 5 years	EUA for 6 to 11 years
Dilution Required	Dilute with 2.2 mL of NS	Dilute with 1.3 mL of NS	No	No
Expiration after opened	12 hours at room temperature **Pfizer doses must remain in vial until ready to use**			
Observation Period	Follow EUA Fact Sheet 15 to 30 minutes based on risk factors			
Dose	0.2 mL	0.2 mL	0.25 mL	0.5 mL
Number of Doses in Primary Series	3 doses 21 days apart followed by a third dose administered at least 8 weeks after the second dose	2 doses 21 days apart	2 doses 28 days apart	2 doses 28 days apart
Immunocompromised Eligible for Additional Vaccination in Primary Series	No	No	0.25 mL at least 28 days after completion of initial series	0.5 mL at least 28 days after completion of initial series
Administration Route and Site	Age 6 months to 2 years: IM into the Vastus Lateralis muscle of anterolateral thigh* Age 3+: IM into the deltoid muscle of the arm			

[^]The vial labels may state “Age 2y to < 5y” and carton labels may state “For age 6 months to < 5 years”. Vials with either printed age range can be used for individuals 6 months through 4 years of age.

*<https://www.cdc.gov/vaccines/hcp/admin/downloads/vaccine-administration-needle-length.pdf>